Immune-based therapeutics for pediatric cancer

Christian M. Capitini, Crystal L. MacKall, Alan S. Wayne

Research output: Contribution to journalArticle

Abstract

Importance of the field: Although most children with cancer are cured, there remain significant limitations of standard treatment, most notably chemotherapy resistance and non-specific toxicities. Novel immune-based therapies that target pediatric malignancies offer attractive adjuncts and/or alternatives to commonly employed cytotoxic regimens of chemotherapy or radiotherapy. Elucidation of the principles of tumor biology and the development of novel laboratory technologies over the last decade have led to substantial progress in bringing immunotherapies to the bedside. Areas covered in this review: Current immunotherapeutic clinical trials in pediatric oncology and the science behind their development are reviewed. What the reader will gain: Most of the immune-based therapies studied to date have been well tolerated, and some have shown promise in the setting of refractory or high-risk malignancies, demonstrating that immunotherapy has the potential to overcome resistance to conventional chemotherapy. Take home message: Some immune-based therapies, such as ch14.18 and MTP-PE, have already been proven effective in phase III randomized trials. Further studies are needed to optimize and integrate other therapies into standard regimens, and to test them in randomized trials for patients with childhood cancer.

Original languageEnglish (US)
Pages (from-to)163-178
Number of pages16
JournalExpert Opinion on Biological Therapy
Volume10
Issue number2
DOIs
StatePublished - Feb 2010
Externally publishedYes

Fingerprint

Pediatrics
Chemotherapy
Neoplasms
Oncology
Drug Therapy
Immunotherapy
Radiotherapy
Refractory materials
Toxicity
Tumors
Therapeutics
Clinical Trials
Technology

Keywords

  • Cancer
  • Childhood
  • Chimeric antigen receptors
  • Cytokines
  • Immunotherapy
  • Monoclonal antibodies
  • Natural killer cells
  • Pediatric
  • Toll-like receptors
  • Vaccines

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery

Cite this

Immune-based therapeutics for pediatric cancer. / Capitini, Christian M.; MacKall, Crystal L.; Wayne, Alan S.

In: Expert Opinion on Biological Therapy, Vol. 10, No. 2, 02.2010, p. 163-178.

Research output: Contribution to journalArticle

Capitini, Christian M. ; MacKall, Crystal L. ; Wayne, Alan S. / Immune-based therapeutics for pediatric cancer. In: Expert Opinion on Biological Therapy. 2010 ; Vol. 10, No. 2. pp. 163-178.
@article{846998216bf4427f856ec328a4f95f0f,
title = "Immune-based therapeutics for pediatric cancer",
abstract = "Importance of the field: Although most children with cancer are cured, there remain significant limitations of standard treatment, most notably chemotherapy resistance and non-specific toxicities. Novel immune-based therapies that target pediatric malignancies offer attractive adjuncts and/or alternatives to commonly employed cytotoxic regimens of chemotherapy or radiotherapy. Elucidation of the principles of tumor biology and the development of novel laboratory technologies over the last decade have led to substantial progress in bringing immunotherapies to the bedside. Areas covered in this review: Current immunotherapeutic clinical trials in pediatric oncology and the science behind their development are reviewed. What the reader will gain: Most of the immune-based therapies studied to date have been well tolerated, and some have shown promise in the setting of refractory or high-risk malignancies, demonstrating that immunotherapy has the potential to overcome resistance to conventional chemotherapy. Take home message: Some immune-based therapies, such as ch14.18 and MTP-PE, have already been proven effective in phase III randomized trials. Further studies are needed to optimize and integrate other therapies into standard regimens, and to test them in randomized trials for patients with childhood cancer.",
keywords = "Cancer, Childhood, Chimeric antigen receptors, Cytokines, Immunotherapy, Monoclonal antibodies, Natural killer cells, Pediatric, Toll-like receptors, Vaccines",
author = "Capitini, {Christian M.} and MacKall, {Crystal L.} and Wayne, {Alan S.}",
year = "2010",
month = "2",
doi = "10.1517/14712590903431022",
language = "English (US)",
volume = "10",
pages = "163--178",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Immune-based therapeutics for pediatric cancer

AU - Capitini, Christian M.

AU - MacKall, Crystal L.

AU - Wayne, Alan S.

PY - 2010/2

Y1 - 2010/2

N2 - Importance of the field: Although most children with cancer are cured, there remain significant limitations of standard treatment, most notably chemotherapy resistance and non-specific toxicities. Novel immune-based therapies that target pediatric malignancies offer attractive adjuncts and/or alternatives to commonly employed cytotoxic regimens of chemotherapy or radiotherapy. Elucidation of the principles of tumor biology and the development of novel laboratory technologies over the last decade have led to substantial progress in bringing immunotherapies to the bedside. Areas covered in this review: Current immunotherapeutic clinical trials in pediatric oncology and the science behind their development are reviewed. What the reader will gain: Most of the immune-based therapies studied to date have been well tolerated, and some have shown promise in the setting of refractory or high-risk malignancies, demonstrating that immunotherapy has the potential to overcome resistance to conventional chemotherapy. Take home message: Some immune-based therapies, such as ch14.18 and MTP-PE, have already been proven effective in phase III randomized trials. Further studies are needed to optimize and integrate other therapies into standard regimens, and to test them in randomized trials for patients with childhood cancer.

AB - Importance of the field: Although most children with cancer are cured, there remain significant limitations of standard treatment, most notably chemotherapy resistance and non-specific toxicities. Novel immune-based therapies that target pediatric malignancies offer attractive adjuncts and/or alternatives to commonly employed cytotoxic regimens of chemotherapy or radiotherapy. Elucidation of the principles of tumor biology and the development of novel laboratory technologies over the last decade have led to substantial progress in bringing immunotherapies to the bedside. Areas covered in this review: Current immunotherapeutic clinical trials in pediatric oncology and the science behind their development are reviewed. What the reader will gain: Most of the immune-based therapies studied to date have been well tolerated, and some have shown promise in the setting of refractory or high-risk malignancies, demonstrating that immunotherapy has the potential to overcome resistance to conventional chemotherapy. Take home message: Some immune-based therapies, such as ch14.18 and MTP-PE, have already been proven effective in phase III randomized trials. Further studies are needed to optimize and integrate other therapies into standard regimens, and to test them in randomized trials for patients with childhood cancer.

KW - Cancer

KW - Childhood

KW - Chimeric antigen receptors

KW - Cytokines

KW - Immunotherapy

KW - Monoclonal antibodies

KW - Natural killer cells

KW - Pediatric

KW - Toll-like receptors

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=76149111984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76149111984&partnerID=8YFLogxK

U2 - 10.1517/14712590903431022

DO - 10.1517/14712590903431022

M3 - Article

C2 - 19947897

AN - SCOPUS:76149111984

VL - 10

SP - 163

EP - 178

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 2

ER -